SEC Form 4 · accession 0000874015-18-000115
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
Sep 20, 2018
Accepted (ET)
Sep 24, 2018 · 8:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $50.80 | Sep 20, 2018 | A | 32,000 | A | Sep 20, 2019 | Sep 19, 2028 | Common Stock | 32,000 | 32,000 | D |
Explanation of responses
- F1Grant of September 20, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on September 20, 2019. The option shall be fully vested and exercisable on September 20, 2022. The option is exercisable to 0 shares on September 20, 2018.